Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk

According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that significantly reduce the level of low-density lipoprotein cholesterol (LDL-C) effectively prevent atherosclerotic cardiovascular diseases (CVD) and com...

Full description

Saved in:
Bibliographic Details
Published inAterotromboz (Online) Vol. 11; no. 2; pp. 56 - 75
Main Authors Kolmakova, T. E., Alekseeva, I. A., Tmoyan, N. A., Ezhov, M. V.
Format Journal Article
LanguageEnglish
Russian
Published REMEDIUM GROUP» Ltd 21.01.2022
Subjects
Online AccessGet full text
ISSN2307-1109
2658-5952
2658-5952
DOI10.21518/2307-1109-2021-11-2-56-75

Cover

Abstract According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that significantly reduce the level of low-density lipoprotein cholesterol (LDL-C) effectively prevent atherosclerotic cardiovascular diseases (CVD) and complications and can slow down the progression of atherosclerosis. The principle “the lower LDL-C, the better” is especially relevant in categories of patients with very high and extreme cardiovascular risk, and therefore, in order to achieve target LDL-C values (≤1.4 is optimal ≤1.0) in this category of patients, high-intensity lipid-lowering therapy should be used. Rosuvastatin remains the most effective statin. Its use makes possible to achieve target lipid values at the starting dose of treatment, enhances adherence to treatment, and also reduces the frequency of side effects associated with the use of high doses of other statins. In addition, the proven ability of rosuvastatin to reduce the volume of atherosclerotic plaque, by reducing the level of pro-inflammatory cytokines and C-reactive protein, normalizing endothelial function, antiplatelet action, that is, rosuvastatin, in addition to its powerful lipid-lowering effect, has anti-inflammatory and anti-ischemic effects. Also, rosuvastatin can be successfully used in the presence of comorbidities, including chronic kidney disease and chronic heart failure. Taking into consideration the urgency of the fight against the COVID-19 pandemic (coronavirus Disease 2019), which covered 220 countries, due to the lack of effective etiotropic drugs, the possibility of using statins, including rosuvastatin, for the treatment of comorbid patients with COVID-19, was evaluated.
AbstractList According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that significantly reduce the level of low-density lipoprotein cholesterol (LDL-C) effectively prevent atherosclerotic cardiovascular diseases (CVD) and complications and can slow down the progression of atherosclerosis. The principle “the lower LDL-C, the better” is especially relevant in categories of patients with very high and extreme cardiovascular risk, and therefore, in order to achieve target LDL-C values (≤1.4 is optimal ≤1.0) in this category of patients, high-intensity lipid-lowering therapy should be used. Rosuvastatin remains the most effective statin. Its use makes possible to achieve target lipid values at the starting dose of treatment, enhances adherence to treatment, and also reduces the frequency of side effects associated with the use of high doses of other statins. In addition, the proven ability of rosuvastatin to reduce the volume of atherosclerotic plaque, by reducing the level of pro-inflammatory cytokines and C-reactive protein, normalizing endothelial function, antiplatelet action, that is, rosuvastatin, in addition to its powerful lipid-lowering effect, has anti-inflammatory and anti-ischemic effects. Also, rosuvastatin can be successfully used in the presence of comorbidities, including chronic kidney disease and chronic heart failure. Taking into consideration the urgency of the fight against the COVID-19 pandemic (coronavirus Disease 2019), which covered 220 countries, due to the lack of effective etiotropic drugs, the possibility of using statins, including rosuvastatin, for the treatment of comorbid patients with COVID-19, was evaluated.
Author Ezhov, M. V.
Alekseeva, I. A.
Kolmakova, T. E.
Tmoyan, N. A.
Author_xml – sequence: 1
  givenname: T. E.
  orcidid: 0000-0002-0316-2940
  surname: Kolmakova
  fullname: Kolmakova, T. E.
  organization: National Medical Research Center of Cardiology
– sequence: 2
  givenname: I. A.
  orcidid: 0000-0001-9685-4569
  surname: Alekseeva
  fullname: Alekseeva, I. A.
  organization: National Medical Research Center of Cardiology
– sequence: 3
  givenname: N. A.
  orcidid: 0000-0002-3617-9343
  surname: Tmoyan
  fullname: Tmoyan, N. A.
  organization: National Medical Research Center of Cardiology
– sequence: 4
  givenname: M. V.
  orcidid: 0000-0002-1518-6552
  surname: Ezhov
  fullname: Ezhov, M. V.
  organization: National Medical Research Center of Cardiology
BookMark eNqVkU9PHSEUxUljk6r1OxD3VOAN_-yqMWpNTNzYNbnDgI92hAnMe2Y-Rr9xmffa7l1xAuf8bi7nDJ2knDxCl4x-4UwwfcU3VBHGqCGcctYU4URIosQHdMql0EQYwU-a_uf7hC5qjT3lSnMjO3GKft-GEF30yS04B7yNL1sS0-xTjfOC560vMC34Lc5bXHLd7aHOMMeEQy64epfTAGXBU_F7n-aY0wpxUIaYm9XtRijY5ddpjA7W54pbdmqyuesRC3jvG2KdjEusvz6jjwHG6i_-nufox93t88138vh0_3Dz7ZE4Jo0gZhiYpIErrgdGKXXSqI2jvQDfe6oluI5R0F0vgzDU91wI1ctOgzOOKdVvztHDkTtk-GmnEl_bJjZDtIeLXF4slDm60VsJQL3hSjituzZPd8x7YyCIjZRamsb6emTt0gTLG4zjfyCj9lCWXUuwawl2Laspy62QVomWvj6mXfviWnx4T_gPJAWesA
Cites_doi 10.1093/eurheartj/ehz455
10.1001/jama.291.9.1071
10.1093/ehjcvp/pvw006
10.21518/2079-701X-2020-14-26-32
10.1185/030079903125002405
10.1056/NEJMoa0706201
10.1093/eurheartj/ehw272
10.1016/j.ijcard.2008.06.055
10.1016/j.jacc.2005.03.077
10.1016/S0140-6736(05)67394-1
10.1097/HJR.0b013e3283316ce8
10.1016/j.amjcard.2020.08.004
10.1056/NEJMoa0810177
10.1007/s11239-014-1142-x
10.1007/s11883-014-0420-6
10.1016/j.jacc.2005.04.064
10.1016/j.acvd.2008.05.010
10.15829/1728-8800-2016-4-29-37
10.1056/NEJMoa1110874
10.1007/s10557-010-6224-1
10.1016/j.phrs.2020.104803
10.1016/j.jcin.2014.06.023
10.1016/j.ahj.2007.11.018
10.1016/j.atherosclerosis.2020.09.008
10.1371/journal.pone.0171682
10.1016/S0140-6736(08)61240-4
10.1016/j.amjcard.2020.09.012
10.4137/CMC.S4324
10.1001/jama.285.13.1711
10.1253/circj.CJ-10-0658
10.20996/1819-6446-2013-9-1-4-14
10.1056/NEJMoa040583
10.1038/s41591-020-0968-3
10.1016/j.tcm.2019.01.001
10.1016/j.cmet.2020.06.015
10.1016/j.dsx.2020.08.023
10.1016/j.jacc.2014.02.615
10.1016/j.jacc.2013.03.058
10.2165/00002512-200825080-00003
10.3810/psm.2010.06.1797
10.1093/eurheartj/ehx144
ContentType Journal Article
DBID AAYXX
CITATION
ADTOC
UNPAY
DOA
DOI 10.21518/2307-1109-2021-11-2-56-75
DatabaseName CrossRef
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2658-5952
EndPage 75
ExternalDocumentID oai_doaj_org_article_6aa0e9275c88428d841ee99af5366869
10.21518/2307-1109-2021-11-2-56-75
10_21518_2307_1109_2021_11_2_56_75
GroupedDBID AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
GROUPED_DOAJ
ADTOC
UNPAY
ID FETCH-LOGICAL-c1695-9dd160f2728d1000c6973c0b5aebe086ac410a84b6f590eb2557b648ac9c177b3
IEDL.DBID DOA
ISSN 2307-1109
2658-5952
IngestDate Wed Aug 27 01:30:46 EDT 2025
Tue Aug 19 21:13:39 EDT 2025
Tue Jul 01 01:18:58 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
Russian
License https://www.aterotromboz.ru/jour/about/editorialPolicies#openAccessPolicy
cc-by-nc-nd
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1695-9dd160f2728d1000c6973c0b5aebe086ac410a84b6f590eb2557b648ac9c177b3
ORCID 0000-0002-1518-6552
0000-0002-0316-2940
0000-0002-3617-9343
0000-0001-9685-4569
OpenAccessLink https://doaj.org/article/6aa0e9275c88428d841ee99af5366869
PageCount 20
ParticipantIDs doaj_primary_oai_doaj_org_article_6aa0e9275c88428d841ee99af5366869
unpaywall_primary_10_21518_2307_1109_2021_11_2_56_75
crossref_primary_10_21518_2307_1109_2021_11_2_56_75
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-01-21
PublicationDateYYYYMMDD 2022-01-21
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-21
  day: 21
PublicationDecade 2020
PublicationTitle Aterotromboz (Online)
PublicationYear 2022
Publisher REMEDIUM GROUP» Ltd
Publisher_xml – name: REMEDIUM GROUP» Ltd
References ref13
ref35
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref39
ref16
ref38
ref19
ref18
ref24
ref46
ref23
ref45
ref26
ref25
ref47
ref20
ref42
ref41
ref22
ref44
ref21
ref43
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref40
References_xml – ident: ref2
  doi: 10.1093/eurheartj/ehz455
– ident: ref37
– ident: ref29
  doi: 10.1001/jama.291.9.1071
– ident: ref1
– ident: ref3
– ident: ref5
– ident: ref8
  doi: 10.1093/ehjcvp/pvw006
– ident: ref7
  doi: 10.21518/2079-701X-2020-14-26-32
– ident: ref17
  doi: 10.1185/030079903125002405
– ident: ref34
  doi: 10.1056/NEJMoa0706201
– ident: ref6
  doi: 10.1093/eurheartj/ehw272
– ident: ref22
  doi: 10.1016/j.ijcard.2008.06.055
– ident: ref25
– ident: ref15
  doi: 10.1016/j.jacc.2005.03.077
– ident: ref9
  doi: 10.1016/S0140-6736(05)67394-1
– ident: ref20
  doi: 10.1097/HJR.0b013e3283316ce8
– ident: ref43
  doi: 10.1016/j.amjcard.2020.08.004
– ident: ref36
  doi: 10.1056/NEJMoa0810177
– ident: ref18
  doi: 10.1007/s11239-014-1142-x
– ident: ref16
  doi: 10.1007/s11883-014-0420-6
– ident: ref13
  doi: 10.1016/j.jacc.2005.04.064
– ident: ref21
  doi: 10.1016/j.acvd.2008.05.010
– ident: ref46
  doi: 10.15829/1728-8800-2016-4-29-37
– ident: ref28
  doi: 10.1056/NEJMoa1110874
– ident: ref23
  doi: 10.1007/s10557-010-6224-1
– ident: ref38
– ident: ref39
  doi: 10.1016/j.phrs.2020.104803
– ident: ref26
  doi: 10.1016/j.jcin.2014.06.023
– ident: ref33
  doi: 10.1016/j.ahj.2007.11.018
– ident: ref45
  doi: 10.1016/j.atherosclerosis.2020.09.008
– ident: ref24
  doi: 10.1371/journal.pone.0171682
– ident: ref35
  doi: 10.1016/S0140-6736(08)61240-4
– ident: ref42
  doi: 10.1016/j.amjcard.2020.09.012
– ident: ref10
  doi: 10.4137/CMC.S4324
– ident: ref11
  doi: 10.1001/jama.285.13.1711
– ident: ref31
  doi: 10.1253/circj.CJ-10-0658
– ident: ref47
  doi: 10.20996/1819-6446-2013-9-1-4-14
– ident: ref12
  doi: 10.1056/NEJMoa040583
– ident: ref40
  doi: 10.1038/s41591-020-0968-3
– ident: ref27
  doi: 10.1016/j.tcm.2019.01.001
– ident: ref41
  doi: 10.1016/j.cmet.2020.06.015
– ident: ref44
  doi: 10.1016/j.dsx.2020.08.023
– ident: ref14
  doi: 10.1016/j.jacc.2014.02.615
– ident: ref30
  doi: 10.1016/j.jacc.2013.03.058
– ident: ref19
  doi: 10.2165/00002512-200825080-00003
– ident: ref32
  doi: 10.3810/psm.2010.06.1797
– ident: ref4
  doi: 10.1093/eurheartj/ehx144
SSID ssib027829645
ssib050729223
ssj0002910378
Score 2.1740174
Snippet According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that...
SourceID doaj
unpaywall
crossref
SourceType Open Website
Open Access Repository
Index Database
StartPage 56
SubjectTerms covid-19
dyslipidemia
extreme cardiovascular risk
low-density lipoprotein cholesterol (ldl-c)
rosuvastatin
very high cardiovascular risk
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZgK_E48EYsL_nANZvEiV_HglpVSK04sFLhYvkVVLUkqzQBpf-Cf8xMkq623Ogtiexx7G-c8cQznwn5UADGnsWYCF7pBCyeSFQJt6rwuQhgssSYC3N8Io7W5edTfrpz1BeGVcIiq226tvnpmqtV26c4quk8kGlADvnGhhRsdcqkukv2BO4tLcje-uTL_rfxMDkkPszH8A4GFjbhmrOJcBQNnEq3BUBHWI6ZZeCQiQRjDXeM08jh_5Dc7-uNHX7bi4sdw3P4mHy_fuUp3uR81Xdu5a_-YXO8VZ-ekEfzcpTuT0WekjuxfkbuHc8b7s_Jn4ORYgLzM2lTUSQ3Ts6mqPduoFPy1kDxZy6FHvW_LCYondUUlsL0En3tYNuBbmaeqKZGIf5GCCy9EdROoe5M9Xo5ibUUJtswtkwxDv4FWR8efP10lMynOCSANh4EGUIusopJpgJuJnihZeEzxy3oDzhU1pd5ZlXpRMV1Bo4-59KJUlmvfS6lK16SRd3U8RWhDr0tkMCEtvjtAUGlldqGSkQeK7ckxTV8ZjORdRhwckbQDYJuEHSDoMOVYYYLI_mSfESktzWQcHt80LQ_zAyREdZmUTPJvVLgsQVV5jFqbSteCKGEXpJyqyf_0fbr21V7Qx4wTMPIQHPzt2TRtX18B4ujzr2fp8FfzD8KaQ
  priority: 102
  providerName: Unpaywall
Title Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk
URI https://www.aterotromboz.ru/jour/article/download/256/278
https://doaj.org/article/6aa0e9275c88428d841ee99af5366869
UnpaywallVersion publishedVersion
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2658-5952
  dateEnd: 20241231
  omitProxy: true
  ssIdentifier: ssj0002910378
  issn: 2658-5952
  databaseCode: DOA
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2658-5952
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssib050729223
  issn: 2307-1109
  databaseCode: M~E
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NS_QwEA6ioL4H8RPXL3LwWmzTZpocVVZEWPHggp5CmqYgSHdZd5Ve3v_w_uN3Jq1LPYngpbSBZGieaWammXnC2HmKGDvhfQSy0hFaPIhUho8qdQmUaLIg1MKM7uF2nN09yafeUV-UE9bSA7cTdwHWxl6LXDql0FUuVZZ4r7WtZAqgIJTuoRnrBVOoSQLtnu7tr0nix_40hLRGC031ceG4usCSmMS6ZSQlC6gulo2oRCKh0jOM2CCiZMSe9Qok_3_YxqKe2ubDvr72LNPNNtvqXEp-2b7KDluZLXbZ-qjbNN9j_4aBJoJqLPmk4kRQHL20mevzhrcFWA2nH7IchS7eLRUZvdQc3Vn-RvFyaWcNn3ZcT5OaBnFf0lj5l8R0jn07uta3dljL8YNpgmROuez7bHwzfLy-jbqTGCJEjA5zLMsE4krkCABtCDjQeeriQlrUAQyKrMuS2KqsgErqGIN1KfMCMmWddkmeF-kBW60ntT9kvKCICUcQoC2tHzhQZnNtywq89FUxYOnnDJtpS7hhMFAJuBjCxRAuhnDBOyOMBJPLAbsiMJY9iDQ7NKAqmU6VzHeqNGDZEsofyD76DdnHbFNQYUWMqpacsNX5bOFP0d2ZF2dBs_E6-js8Y2vj-4fL5_9IPvYa
linkProvider Directory of Open Access Journals
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZgK_E48EYsL_nANZvEiV_HglpVSK04sFLhYvkVVLUkqzQBpf-Cf8xMkq623Ogtiexx7G-c8cQznwn5UADGnsWYCF7pBCyeSFQJt6rwuQhgssSYC3N8Io7W5edTfrpz1BeGVcIiq226tvnpmqtV26c4quk8kGlADvnGhhRsdcqkukv2BO4tLcje-uTL_rfxMDkkPszH8A4GFjbhmrOJcBQNnEq3BUBHWI6ZZeCQiQRjDXeM08jh_5Dc7-uNHX7bi4sdw3P4mHy_fuUp3uR81Xdu5a_-YXO8VZ-ekEfzcpTuT0WekjuxfkbuHc8b7s_Jn4ORYgLzM2lTUSQ3Ts6mqPduoFPy1kDxZy6FHvW_LCYondUUlsL0En3tYNuBbmaeqKZGIf5GCCy9EdROoe5M9Xo5ibUUJtswtkwxDv4FWR8efP10lMynOCSANh4EGUIusopJpgJuJnihZeEzxy3oDzhU1pd5ZlXpRMV1Bo4-59KJUlmvfS6lK16SRd3U8RWhDr0tkMCEtvjtAUGlldqGSkQeK7ckxTV8ZjORdRhwckbQDYJuEHSDoMOVYYYLI_mSfESktzWQcHt80LQ_zAyREdZmUTPJvVLgsQVV5jFqbSteCKGEXpJyqyf_0fbr21V7Qx4wTMPIQHPzt2TRtX18B4ujzr2fp8FfzD8KaQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficiency+of+high-intensity+therapy+with+rosuvastatin+for+secondary+prevention+of+cardiovascular+complications+in+patients+with+a+very+high+risk&rft.jtitle=Aterotromboz+%28Online%29&rft.au=T.+E.+Kolmakova&rft.au=I.+A.+Alekseeva&rft.au=N.+A.+Tmoyan&rft.au=M.+V.+Ezhov&rft.date=2022-01-21&rft.pub=REMEDIUM+GROUP%C2%BB+Ltd&rft.issn=2307-1109&rft.eissn=2658-5952&rft.volume=11&rft.issue=2&rft.spage=56&rft.epage=75&rft_id=info:doi/10.21518%2F2307-1109-2021-11-2-56-75&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_6aa0e9275c88428d841ee99af5366869
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2307-1109&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2307-1109&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2307-1109&client=summon